Cocrystal Pharma logo
Cocrystal Pharma
COCP | NASDAQ
Chart Builder DCF Calculator
$1.00
+$0.02 (+2.03%)
At close: Nov 16, 2026, 3:59 PM ET
$1.00
$0.00 (-0.03%)
After-hours: Nov 16, 2026, 7:50 PM ET

Cocrystal Pharma Company Profile

Company profile explained

Company Profile

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Key Executives

Name Position
James R. Sapirstein Chief Executive Officer
James J. Martin CFO & Corporate Secretary
Roger D. Kornberg Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board
Sam Lee Chief Scientific Officer, Co-Founder & President

Latest SEC Filings

Date Type Title
Sep 09, 2026 8-K Current Report
Aug 21, 2026 3 Filing
Aug 18, 2026 8-K Current Report
Aug 17, 2026 8-K Current Report
Aug 13, 2026 10-Q Quarterly Report
Aug 07, 2026 SC 13D Filing
Aug 07, 2026 SC 13D/A [Amend] Filing
Aug 06, 2026 4 Filing
Aug 05, 2026 4 Filing
Aug 03, 2026 8-K Current Report
View All SEC Filings ➞
Cocrystal Pharma
Cocrystal Pharma logo
Country United States
IPO Date Feb 22, 2012
Industry Biotechnology
Sector Healthcare
Employees 10
CEO James E. Sapirstein

Contact Details

19805 North Creek Parkway Bothell, Washington 98011 United States

Stock Details

Ticker Symbol COCP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001412486
CUSIP Number 19188J409
ISIN Number US19188J4094
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.